UY39574A - Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene - Google Patents
Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contieneInfo
- Publication number
- UY39574A UY39574A UY0001039574A UY39574A UY39574A UY 39574 A UY39574 A UY 39574A UY 0001039574 A UY0001039574 A UY 0001039574A UY 39574 A UY39574 A UY 39574A UY 39574 A UY39574 A UY 39574A
- Authority
- UY
- Uruguay
- Prior art keywords
- pharmaceutical composition
- composition containing
- treat cancer
- compound useful
- macrocyclic compound
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente descripción se refiere a compuestos macrocíclicos, composiciones farmacéuticas que contienen compuestos macrocíclicos y métodos para usar compuestos macrocíclicos para tratar enfermedades, tales como el cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126722P | 2020-12-17 | 2020-12-17 | |
US202163279850P | 2021-11-16 | 2021-11-16 | |
US202163284789P | 2021-12-01 | 2021-12-01 | |
US202163289014P | 2021-12-13 | 2021-12-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39574A true UY39574A (es) | 2022-07-29 |
Family
ID=82058646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039574A UY39574A (es) | 2020-12-17 | 2021-12-17 | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240182487A1 (es) |
EP (1) | EP4262796A1 (es) |
JP (1) | JP2023553835A (es) |
KR (1) | KR20230121773A (es) |
AU (1) | AU2021401741A1 (es) |
CA (1) | CA3202770A1 (es) |
IL (1) | IL303419A (es) |
MX (1) | MX2023007162A (es) |
TW (1) | TW202241911A (es) |
UY (1) | UY39574A (es) |
WO (1) | WO2022133037A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023240138A1 (en) * | 2022-06-08 | 2023-12-14 | Blossomhill Therapeutics, Inc. | Indazole containing macrocycles and their use |
TW202413377A (zh) * | 2022-06-08 | 2024-04-01 | 美商榮山醫藥股份有限公司 | 吲唑巨環化合物及其用途 |
WO2024022286A1 (zh) * | 2022-07-27 | 2024-02-01 | 上海和誉生物医药科技有限公司 | 大环egfr抑制剂及其制备方法和药学上的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
EP2822953B9 (en) * | 2012-03-06 | 2017-06-21 | Pfizer Inc | Macrocyclic derivatives for the treatment of proliferative diseases |
TW202039509A (zh) * | 2018-12-21 | 2020-11-01 | 美商銳新醫藥公司 | 參與協同結合之化合物及其用途 |
-
2021
- 2021-12-16 KR KR1020237021826A patent/KR20230121773A/ko unknown
- 2021-12-16 IL IL303419A patent/IL303419A/en unknown
- 2021-12-16 JP JP2023532465A patent/JP2023553835A/ja active Pending
- 2021-12-16 MX MX2023007162A patent/MX2023007162A/es unknown
- 2021-12-16 CA CA3202770A patent/CA3202770A1/en active Pending
- 2021-12-16 EP EP21907788.0A patent/EP4262796A1/en active Pending
- 2021-12-16 US US18/257,166 patent/US20240182487A1/en active Pending
- 2021-12-16 AU AU2021401741A patent/AU2021401741A1/en active Pending
- 2021-12-16 TW TW110147239A patent/TW202241911A/zh unknown
- 2021-12-16 WO PCT/US2021/063721 patent/WO2022133037A1/en active Application Filing
- 2021-12-17 UY UY0001039574A patent/UY39574A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4262796A1 (en) | 2023-10-25 |
CA3202770A1 (en) | 2022-06-23 |
IL303419A (en) | 2023-08-01 |
MX2023007162A (es) | 2023-06-29 |
TW202241911A (zh) | 2022-11-01 |
US20240182487A1 (en) | 2024-06-06 |
WO2022133037A1 (en) | 2022-06-23 |
AU2021401741A1 (en) | 2023-06-29 |
KR20230121773A (ko) | 2023-08-21 |
JP2023553835A (ja) | 2023-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39574A (es) | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene | |
DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2020000633A2 (es) | Compuestos macrocíclicos y usos de los mismos | |
CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
DOP2018000222A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes | |
CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
CL2018000952A1 (es) | Compuestos útiles como inmunomoduladores | |
CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
MX2017006382A (es) | Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer. | |
UY36702A (es) | Piridinas sustituidas y métodos de uso | |
CO6341623A2 (es) | Compuestos organicos | |
CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
CL2023000061A1 (es) | Macrociclos y su uso | |
BR112020008664A8 (pt) | Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo | |
GT200500311A (es) | Compuestos organicos | |
CL2011000258A1 (es) | Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion. | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
CO2020003475A2 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos | |
ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
CO2022017969A2 (es) | Compuestos de imidazopiridazina con actividad como inhibidores de alk2 | |
GT200700020A (es) | Compuestos y derivados de dibencilamina | |
UY39779A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CO2022014837A2 (es) | Células t v delta1+ para el tratamiento de neoplasias mieloides |